Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P19367
UPID:
HXK1_HUMAN
Alternative names:
Brain form hexokinase; Hexokinase type I; Hexokinase-A
Alternative UPACC:
P19367; E9PCK0; O43443; O43444; O75574; Q5VTC3; Q96HC8; Q9NNZ4; Q9NNZ5
Background:
Hexokinase-1, also known as Brain form hexokinase, Hexokinase type I, and Hexokinase-A, plays a pivotal role in glucose metabolism. It catalyzes the phosphorylation of hexoses to hexose 6-phosphate, marking the initial step of glycolysis. Beyond its metabolic functions, Hexokinase-1 is involved in innate immunity by acting as a pattern recognition receptor for bacterial peptidoglycan.
Therapeutic significance:
Hexokinase-1 is implicated in several diseases, including Hexokinase deficiency, characterized by nonspherocytic hemolytic anemia, and various neurological and visual disorders. Its involvement in these conditions highlights its potential as a target for therapeutic intervention, aiming to alleviate symptoms or modify disease progression.